Document:

Document

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL. SUCH EXCLUDED INFORMATION HAS BEEN MARKED WITH “[***]”.

FOURTH AMENDMENT
This FOURTH AMENDMENT (“Fourth Amendment”) is entered into on December 12, 2022 (“Fourth Amendment Effective Date”) by and between Daewoong Pharmaceutical Co., Ltd. (“DAEWOONG”) and Evolus Inc. (“EVOLUS”) and amends that certain License & Supply Agreement between the Parties dated September 30, 2013, as amended by that certain First Amendment dated February 26, 2014, that certain Second Amendment dated July 15, 2014 and that certain Third Amendment dated March 23, 2021 (collectively, the “Original Agreement”).
The Parties, for their mutual benefit, now wish to amend the Original Agreement. Capitalized terms herein used which are not herein defined shall have the respective meanings ascribed to them in the Original Agreement.  All references to the term “Agreement” in the Original Agreement shall be deemed to include all of the terms and conditions of this Fourth Amendment. The term “Third Amendment Effective Date” shall mean March 23, 2021.
NOW, THEREFORE, in consideration of the mutual promises hereinafter set forth, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:
1.AMENDMENTS.
(a)Definition of Territory.  The definition of “Territory” in Section 1.36 of the Original Agreement is hereby amended to remove all references to Russia, and all rights to distribution of the Product in Russia shall hereby revert to DAEWOONG.
(b)Annex B Amendment(1).  Annex B of the Original Agreement is hereby amended to remove all references to Russia, and all rights to distribution of the Product in Russia shall hereby revert to DAEWOONG.
(c)Transfer of Russia related Regulatory Approval application.  EVOLUS shall work together in good faith with DAEWOONG to transfer all regulatory materials related to the Regulatory Approval and Marketing Authorization developed by EVOLUS for the Russian territory.  
(d)Annex B Amendment(2)-Pricing for European Territories.  The Price per Unit for the Product in the European Territories set forth in the Annex B of Third Amendment to the Original Agreement is hereby amended and restated to be:
(1)Pricing for [***] Commercial lots of Product: The Price per Unit for the Product in the European Territories for the [***] shipped commercial lots dated as of the Third Amendment shall be as originally set forth in the Third Amendment to the Original Agreement, dated as of the Third Amendment Effective Date.
(2)Transfer Price: After the [***] shipped commercial lots, the Price per Unit for the Product in the European Territories is hereby amended and restated to be [***] per vial (the “European Transfer Price”).  The European Transfer Price shall be effective until the [***] anniversary of the Fourth Amendment Effective Date.  The Parties will meet annually in [***] to agree to the European Transfer Price that will apply for the following [***] from the Anniversary of Fourth Amendment Effective Date. The Parties shall use commercially reasonable efforts to establish a European Transfer Price intended to minimize the True-Up payable during [***], provided, however, that the European Transfer Price will not be set to less than [***] per vial. 
(3)Additional Quarterly True Up.  In addition to the European Transfer Price, within [***] after each calendar quarter, EVOLUS shall: (i) calculate the Net Sales in each country within the European Territory in U.S. Dollars, provided that the exchange rate for conversion of the local currency into U.S. Dollars shall be calculated on the day Net Sales are made, or the preceding business day if Net Sales are not made on a business day, according to the dollar exchange rate for such local currency (ii) provide to DAEWOONG a calculation of Net Sales in each country within the European Territory (the "Net Sales Report"), (iii) calculate a quarterly true-up based on the Net Sales Report (the “True Up”).
(a)“Unit Quantity Sold” for the Product means [***] during the calendar quarter.

(b)“True Up Calculation” means [***].
(c)“Floor price” for the Product shall mean [***] per vial.
(d)“Floor Price Calculation” means [***].
(e)Payment of the True Up.  If the True Up Calculation for each country is a positive number, then EVOLUS shall pay to DAEWOONG the amount of the True Up within [***] after issuance of the invoice from DAEWOONG.  If the True Up Calculation for each country is a negative number, then DAEWOONG shall issue a credit note to EVOLUS in the amount of the True Up within [***] after DAEWOONG’s receiving of the Net Sales Report. If the True Up Calculation is a positive number for each country, the True Up shall be equal to the “True Up Calculation” for such country. If the True Up Calculation is negative number for each country, the True Up shall be equal to the lesser of (i) the “True Up Calculation” for such country or (ii) the “Floor Price Calculation” for such country.
(f)Example – Payment by EVOLUS: For illustrative purposes: [***] 
i.True Up Calculation = [***] 
ii.EVOLUS shall pay [***] to DAEWOONG.
(g)Example – Payment by DAEWOONG: For illustrative purposes: [***]
i.True Up Calculation = [***]
ii.Floor Price Calculation = [***]
iii.DAEWOONG shall issue [***] credit note to EVOLUS as the lesser of the True Up Calculation and the Floor Price Calculation.
(h)Net Sales Clarification. For purposes of this Section, the definition of “Net Sales” shall be aligned to EVOLUS’ Accounting Principles as they are reported by EVOLUS in its securities filings and as consistently applied across any other agreements EVOLUS has to calculate Net Sales. To the extent any adjustments to Net Sales are allocable to multiple countries within the European Territories, [***].
(i)DAEWOONG Audit Right.  Pursuant to Section 1.27 of the Original Agreement, DAEWOONG shall have the right to audit the Net Sales Report.  
(4)Reporting Obligations. EVOLUS shall prepare the materials set forth on Appendix B on the timetables set forth therein (the “Required Plans”). In the event that EVOLUS fails to provide the Required Plans and fails to correct the failure within [***] of notice from DAEWOONG, DAEWOONG shall have the option upon written notice to EVOLUS to revert the European Transfer Price and any associated purchase volumes to the terms set forth in the Third Amendment to the Original Agreement. 
(e)Launch timeline for European Territories. EVOLUS shall use Commercially Reasonable Efforts to launch the Product on the schedule and in the total volumes set forth on Appendix A.
2.COUNTERPARTS.  This Fourth Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original but all of which taken together shall constitute one and the same instrument.  Signatures to this Fourth Amendment transmitted by facsimile, email, portable document format (.pdf) or by any other electronic means intended to preserve the original graphic and pictorial appearance of this Agreement shall have the same effect as the physical delivery of the paper document bearing original signatures. 
3.NO OTHER AMENDMENTS.  Except as herein set forth, the Original Agreement has not been modified and, as amended by this Fourth Amendment, remains of full force and effect. To the extent there are any inconsistencies or ambiguities between the specific subject matter of this Fourth Amendment and the Original Agreement, the terms of this Fourth Amendment shall supersede the Original Agreement.
Page 2

IN WITNESS WHEREOF, the duly authorized representatives of the Parties have executed this Fourth Amendment effective as of the Fourth Amendment Effective Date.

						
	DAEWOONG PHARMACEUTICAL CO., LTD.
	EVOLUS INC.
	By:    /s/Seng-Ho Jeon            
Name:     Seng-Ho Jeon
Title:      CEO & President    
	By:    /s/David Moatazedi            
Name:    David Moatazedi    
Title:    CEO & President

		

Page 3

Appendix A
Launch Schedule
[***]

Page 4

Appendix B
Required Plans
[***]
Page 5EX-10.1

 Exhibit 10.1 

THIS NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT
ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE MAKER THAT SUCH REGISTRATION IS NOT
REQUIRED. 
 PROMISSORY NOTE 
  

			
	$1,500,000.00	  	As of December 13, 2022

 Catcha Investment Corp (“Maker”) promises to pay to the order of Catcha Holdings LLC or its successors or assigns
(“Payee”) the principal sum of up to One Million Five Hundred Thousand Dollars and No Cents ($1,500,000.00) in lawful money of the United States of America, on the terms and conditions described below. 

1. Principal. The principal balance of this Note shall be repayable on the consummation of the Maker’s initial merger, stock exchange, asset
acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities (a “Business Combination”). Payee understands that if a Business Combination is not consummated, this
Note will not be repaid and all amounts owed hereunder will be forgiven except to the extent that the Maker has funds available to it outside of its trust account established in connection with its initial public offering. 

2. Interest. No interest shall accrue on the unpaid principal balance of this Note. 

3. Application of Payments. All payments shall be applied first to payment in full of any costs incurred in the collection of any sum due under this
Note, including (without limitation) reasonable attorneys’ fees, then to the payment in full of any late charges and finally to the reduction of the unpaid principal balance of this Note. 

4. Events of Default. The following shall constitute Events of Default: 

(a) Failure to Make Required Payments. Failure by Maker to pay the principal of this Note within five (5) business days following the date when
due. 
 (b) Voluntary Bankruptcy, Etc. The commencement by Maker of a voluntary case under the Federal Bankruptcy Code, as now constituted or
hereafter amended, or any other applicable federal or state bankruptcy, insolvency, reorganization, rehabilitation or other similar law, or the consent by it to the appointment of or taking possession by a receiver, liquidator, assignee, trustee,
custodian, sequestrator (or other similar official) of Maker or for any substantial part of its property, or the making by it of any assignment for the benefit of creditors, or the failure of Maker generally to pay its debts as such debts become
due, or the taking of corporate action by Maker in furtherance of any of the foregoing. 
 (c) Involuntary Bankruptcy, Etc. The entry of a decree or
order for relief by a court having jurisdiction in the premises in respect of maker in an involuntary case under the Federal Bankruptcy Code, as now or hereafter constituted, or any other applicable federal or state bankruptcy, insolvency or other
similar law, or appointing a receiver, liquidator, assignee, custodian, trustee, sequestrator (or similar official) of Maker or for any substantial part of its property, or ordering the winding-up or
liquidation of its affairs, and the continuance of any such decree or order unstayed and in effect for a period of 60 consecutive days. 
 5.
Remedies. 
 (a) Upon the occurrence of an Event of Default specified in Section 4(a), Payee may, by written notice to Maker, declare this Note
to be due and payable, whereupon the principal amount of this Note, and all other amounts payable thereunder, shall become immediately due and payable without presentment, demand, protest or other notice of any kind, all of which are hereby
expressly waived, anything contained herein or in the documents evidencing the same to the contrary notwithstanding. 

 (b) Upon the occurrence of an Event of Default specified in Sections 4(b) and 4(c), the unpaid principal
balance of, and all other sums payable with regard to, this Note shall automatically and immediately become due and payable, in all cases without any action on the part of Payee. 

6. Conversion. Upon consummation of a Business Combination, the Payee shall have the option, but not the obligation, to convert the principal balance
of this Note, in whole or in part at the option of the Payee, into warrants (“Warrants”) of the Maker at a price of $1.50 per Warrant, each Warrant being identical to the “private placement warrant” (as defined in Maker’s
prospectus dated February 17, 2021). As promptly after notice by Payee to Maker to convert the principal balance of this Note, which must be made at least 24 hours prior to the consummation of the Business Combination, as reasonably practicable
and after Payee’s surrender of this Note, Maker shall have issued and delivered to Payee, without any charge to Payee, in book-entry form or a certificate or certificates (issued in the name(s) requested by Payee) for the number of Warrants of
Maker issuable upon the conversion of this Note. 
 7. Waivers. Maker and all endorsers and guarantors of, and sureties for, this Note waive
presentment for payment, demand, notice of dishonor, protest, and notice of protest with regard to the Note, all errors, defects and imperfections in any proceedings instituted by Payee under the terms of this Note, and all benefits that might
accrue to Maker by virtue of any present or future laws exempting any property, real or personal, or any part of the proceeds arising from any sale of any such property, from attachment, levy or sale under execution, or providing for any stay of
execution, exemption from civil process, or extension of time for payment; and Maker agrees that any real estate that may be levied upon pursuant to a judgment obtained by virtue hereof, on any writ of execution issued hereon, may be sold upon any
such writ in whole or in part in any order desired by Payee. 
 8. Unconditional Liability. Maker hereby waives all notices in connection with the
delivery, acceptance, performance, default, or enforcement of the payment of this Note, and agrees that its liability shall be unconditional, without regard to the liability of any other party, and shall not be affected in any manner by any
indulgence, extension of time, renewal, waiver or modification granted or consented to by Payee, and consents to any and all extensions of time, renewals, waivers, or modifications that may be granted by Payee with respect to the payment or other
provisions of this Note, and agree that additional makers, endorsers, guarantors, or sureties may become parties hereto without notice to them or affecting their liability hereunder. 

9. Notices. Any notice called for hereunder shall be deemed properly given if (i) sent by certified mail, return receipt requested,
(ii) personally delivered, (iii) dispatched by any form of private or governmental express mail or delivery service providing receipted delivery, (iv) sent by telefacsimile or (v) sent by
e-mail, to the following addresses or to such other address as either party may designate by notice in accordance with this Section: 

If to Maker: 
 Catcha Investment Corp 

Level 42, Suntec Tower Three 
 8 Temasek Blvd 

If to Payee: 
 Catcha Holdings LLC 

45-7 The Boulevard 
 Mid
Valley City 
 Lingkaran Syed Putra 
 59200 Kuala Lumpur 

Malaysia 

 Notice shall be deemed given on the earlier of (i) actual receipt by the receiving party, (ii) the
date shown on a telefacsimile transmission confirmation, (iii) the date on which an e-mail transmission was received by the receiving party’s on-line access
provider (iv) the date reflected on a signed delivery receipt, or (vi) two (2) Business Days following tender of delivery or dispatch by express mail or delivery service. 

10. Construction. This Note shall be construed and enforced in accordance with the domestic, internal law, but not the law of conflict of laws, of the
State of New York. 
 11. Severability. Any provision contained in this Note which is prohibited or unenforceable in any jurisdiction shall, as to
such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render
unenforceable such provision in any other jurisdiction. 
 12. Trust Waiver. Notwithstanding anything herein to the contrary, the Payee hereby waives
any right, title, interest or claim of any kind (“Claim”) in or to any distribution of or from Maker’s trust account established in connection with the Maker’s initial public offering (the “Trust Account”), and hereby
agrees not to seek recourse, reimbursement, payment or satisfaction for any Claim against the Trust Account for any reason whatsoever. Notwithstanding the foregoing, the Payee does not waive any Claims, and does not waive its rights to seek
recourse, reimbursement, payment or satisfaction for any Claim, against the Trust Account for distributions of remaining funds released to the Maker from the Trust Account following redemptions or other distributions to Maker’s public
shareholders. 
 [Remainder of Page Intentionally Left Blank] 

 IN WITNESS WHEREOF, Maker, intending to be legally bound hereby, has caused this Note to be duly executed by
the undersigned as of the day and year first above written. 
  

			
	Catcha Investment Corp
	By:	 	 /s/ Patrick Grove

	Name:	 	Patrick Grove
	Title:	 	Chairman and Chief Executive Officer

 [Signature Page to Promissory Note] 

 Accepted and agreed as of the date first written above. 

Catcha Holdings LLC 
  

			
	By:	 	 /s/ Luke Elliott

	Name:	 	Luke Elliott
	Title:	 	Manager

 [Signature Page to Promissory Note]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00351-of-00352.parquet"}]]